Nuwellis (NUWE)
NASDAQ:NUWE
NUWE Stock Chart & Stats
$1.76
-$0.08(-7.15%)
At close: 4:00 PM EST
$1.76
-$0.08(-7.15%)
Day’s Range― - ―
52-Week Range$0.96 - $45.40
Previous CloseN/A
Volume102.02K
Average Volume (3M)289.18K
Market Cap
$2.51M
Enterprise Value$222.39K
Total Cash (Recent Filing)$1.08M
Total Debt (Recent Filing)$328.00K
Price to Earnings (P/E)―
Beta1.78
Next Earnings
May 12, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.50
Shares Outstanding2,310,477
10 Day Avg. Volume82,161
30 Day Avg. Volume289,177
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.58
Price to Sales (P/S)1.45
P/FCF Ratio-1.10
Enterprise Value/Market Cap0.09
Enterprise Value/Revenue0.03
Enterprise Value/Gross Profit0.04
Enterprise Value/Ebitda-0.03
Forecast
1Y Price Target
$1.31Price Target Upside-25.57% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.83
Revenue Forecast (FY)$9.01M
Bulls Say, Bears Say
Bulls Say
Commercial Execution And Supply StabilityShift to a direct-selling model in the United States and migration of manufacturing to a contract partner is intended to improve commercial execution, stabilize supply, and enhance product quality, which could increase sales efficiency.
Earnings And Revenue MomentumResults modestly exceeded analyst expectations as stronger console sales, higher utilization across the installed base, and improved circuit pricing supported revenue momentum.
Product Portfolio Expansion And Clinical CapabilityAcquisition of Rendiatech integrates real-time urine flow and kidney injury monitoring into the Aquadex platform, expanding offerings for hospital customers and strengthening the critical care value proposition.
Bears Say
Financing Needs And Dilution RiskLimited cash runway and the likely need for additional capital raise introduce a risk of shareholder dilution and create uncertainty about the path to sustainable profitability.
Integration And Commercialization UncertaintyUndefined integration timelines for acquired technologies and an unclear commercialization strategy create uncertainty about when acquisitions will meaningfully contribute to sales.
International Revenue SustainabilityA spike in international consumable sales was driven by exiting certain markets, making those sales non-recurring and weakening the sustainability of international revenue growth.
Nuwellis News
NUWE FAQ
What was Nuwellis’s price range in the past 12 months?
Nuwellis lowest stock price was $0.96 and its highest was $45.40 in the past 12 months.
What is Nuwellis’s market cap?
Nuwellis’s market cap is $2.51M.
When is Nuwellis’s upcoming earnings report date?
Nuwellis’s upcoming earnings report date is May 12, 2026 which is in 30 days.
How were Nuwellis’s earnings last quarter?
Nuwellis released its earnings results on Mar 10, 2026. The company reported -$1.5 earnings per share for the quarter, beating the consensus estimate of -$1.56 by $0.06.
Is Nuwellis overvalued?
According to Wall Street analysts Nuwellis’s price is currently Overvalued.
Does Nuwellis pay dividends?
Nuwellis does not currently pay dividends.
What is Nuwellis’s EPS estimate?
Nuwellis’s EPS estimate is -1.
How many shares outstanding does Nuwellis have?
Nuwellis has 2,310,477 shares outstanding.
What happened to Nuwellis’s price movement after its last earnings report?
Nuwellis reported an EPS of -$1.5 in its last earnings report, beating expectations of -$1.56. Following the earnings report the stock price went up 0.775%.
Which hedge fund is a major shareholder of Nuwellis?
Currently, no hedge funds are holding shares in NUWE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuwellis
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
NUWE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mixed picture: management highlighted operational strengthening (manufacturing transition, margin improvement, focused commercial deployment), strategic clarity (cardiorenal focus, pediatric IP and NIH funding), and pockets of strong product performance (Q4 revenue growth, 208% increase in U.S. console sales). Offsetting these positives were continued top-line pressure for the year (full-year revenue down 5%), sizable net losses ($17.5M), significant cash burn with only ~$1.2M cash on hand at year-end, declines in critical care revenue, and reliance on financings and one-time accounting charges. Overall, the transcript presents balanced progress on restructuring and margin work but material near-term financial constraints and execution risks remain.View all NUWE earnings summariesNUWE Stock 12 Month Forecast
Average Price Target
$1.31
▼(-25.57% Downside)
Technical Analysis
Aethlon Medical
―
PAVmed
―
Catheter Precision
―
Bone Biologics
―
Heart Test Laboratories, Inc.
―
Ownership Overview
47.61% Insiders
0.04% Mutual Funds
4.65% Other Institutional Investors
47.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---